Key result
Review outlines novel methods to assess platelet heterogeneity and its therapeutic implications in hemostasis and cancer.
Why the study?
Considerable intra-individual heterogeneity in platelet structure, age, and activation properties has major implications for hemostasis, thrombosis, thromboinflammation, and therapeutic targeting.
This review provides an overview of methodologies to assess platelet heterogeneity, which has implications for hemostasis, thrombosis, and therapeutic targeting.
Answers are grounded in this paper and cite their sources.
Platelet heterogeneity testing should not yet inform clinical decisions; leaves open targeted therapies in hemostasis and cancer.
Blood platelets are crucial in hemostasis, thrombosis, and thromboinflammation. Current evidence highlights the considerable heterogeneity within individuals in platelet structure, age, and activation properties. This heterogeneity has major implications for the diverse functions of platelets in physiology and pathophysiology, extending to therapeutic targeting in hemostasis and cancer. In this review, we provide a general concept of heterogeneity or diversity of platelet populations, with emphasis on the diagnostic and advanced methodologies to assess and study differences between platelets. We describe conventional and novel approaches to address clinical and in research questions addressing platelet heterogeneity and discuss strengths and limitations of the available techniques.
No takes yet. Share an insight, caveat, or question.
Thiele et al. (2025) conducted a review in Platelet heterogeneity in hemostasis, thrombosis, and thromboinflammation. This review outlines conventional and novel methodologies to assess platelet heterogeneity, highlighting its implications for physiology, pathophysiology, and therapeutic targeting in hemostasis and cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: